07 JOHNSON & JOHNSON
Headquartered in New Brunswick, NJ, Johnson & Johnson (J&J) operates in more than 60 countries while its phar- maceutical and healthcare products are supplied to over
200 countries. The Pharmaceutical segment contributes nearly
47% of J&J’s total revenues. The segment reported 2016 revenues
of $33.5 billion—a 7% increase over 2015—and comprises several franchises: Immunology, Infectious Disease, Neuroscience,
Oncology, and Cardiovascular and Metabolics. The major blockbuster drugs under the Immunology franchise are Remicade, Stelara, and Simponi/Simponi Aria. The franchise revenues reported
growth of 7% to $12 billion in 2016.
J&J’s Oncology franchise grew 24% to $6 billion during 2016,
driven by increased sales of Imbruvica and a strong uptake of
Darzalex. During the year Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, entered
several cancer collaborations. First it teamed up with Tesaro for
exclusive rights to the investigational compound niraparib in
prostate cancer. Niraparib is an orally administered, once daily,
potent, and highly selective poly polymerase (PARP) inhibitor,
currently in late-stage development for patients with metastatic
breast cancer and ovarian cancer. Janssen will develop and commercialize niraparib for patients with prostate cancer worldwide,
except in Japan. Tesaro received an upfront payment of $35 million, and is eligible to receive additional milestone payments of
up to $415 million.
With Bristol-Myers Squibb (BMS), Janssen entered a clinical
research collaboration to evaluate BMS’ immuno-oncology drug
Opdivo (nivolumab) and Janssen’s Live Attenuated Double–
Deleted (LADD) Listerial monocytogenes cancer immunotherapy,
expressing mesothelin and EGFRvIII (JNJ-64041757), in patients
with non-small cell lung cancer (NSCLC). Opdivo is a human antibody designed to alleviate immune suppression. JNJ-64041757 is
designed to induce an immune response against NSCLC tumors.
Later in the year, Janssen entered into a master clinical trial
collaboration and supply agreement with Onyx Pharmaceuti-
cals, a subsidiary of Amgen, to evaluate the efficacy and safety of
CD38-directed immunotherapy daratumumab (DARZALEX) in
combination with a proteasome inhibitor (PI) carfilzomib (KY-
PROLIS) and dexamethasone. The agreement covers all potential
opportunities for combining daratumumab and carfilzomib to
treat cancer. Janssen licensed daratumumab from Genmab and
is responsible for all global develop-
ment, marketing and manufactur-
ing. Carfilzomib is developed and
commercialized by Amgen.
Industrial bioscience company
Amyris entered into a research
agreement with Janssen facilitated
by Johnson & Johnson Innovation.
The collaboration will use Amyris’s
µPharm platform technology to de-
velop a customized library of natural
and natural-like compounds to test
against Janssen’s therapeutic target.
Amyris’s µPharm platform technol-
ogy enables an integrated discovery
and production process for thera-
peutic compounds. It provides access
to scarce natural compounds and
also creates new diversity based on natural compound scaffolds.
Janssen Biotech also licensed Ionis Pharmaceuticals’ IO-
NIS-JBI1-2.5Rx, an oral antisense drug for the treatment of
a GI autoimmune disease, for $10 million. Janssen assumes
all global development, regulatory and commercialization re-
sponsibilities after Ionis completes the IND-enabling studies.
Ionis is eligible to receive as much as $800 million in devel-
opment, regulatory and sales milestones and license fees for
three programs, as well as royalties on sales from any product
that is successfully commercialized.
Janssen Pharmaceutica NV divested five anesthesia and pain
management injectable products to Piramal Enterprises’ wholly
owned Critical Care subsidiary in the UK for $155 million. The
products include five injectable versions of Janssen’s Sublimaze
(fentanyl citrate), Sufenta (sufentanil citrate), Rapifen (
alfent-anil hydrochloride), Dipidolor (piritramide), and Hypnomidate
(etomidate), which are currently marketed in more than 50 countries. Piramal acquired the brand names and related IP, including how to make both the API and the finished dosage forms of
the products. The acquisition does not include the transfer of any
manufacturing facilities or employees. Janssen will continue to
supply finished dosage forms for up to three years and API for up
to five years, and will continue to sell the products on behalf of
Piramal until the marketing authorizations or relevant business
relations are transferred to Piramal. CP
J&J BUYS ACTELION FOR $30B
Actelion to spin out R&D ops and assets
During the year Johnson & Johnson entered into a mega deal to acquire Actelion Ltd. for approximately $30 billion.
Actelion, based in Allschwil, Switzerland, has a franchise of differentiated, innovative products for pulmonary arterial hypertension
As part of the transaction, Actelion will spin out its drug discovery operations and early-stage clinical development assets into a newly
created Swiss biopharma company, R&D NewCo. Johnson & Johnson also received an option on ACT-132577, a product being devel-
oped for resistant hypertension currently in Phase II development.
J&J’s headquarters in New
Brunswick, NJ. A 24% increase in
oncology sales helped boost rev-
enues to $33.5 billion for the year.